Neoleukin Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>NT</div>
Neoleukin Therapeutics Net Cash Flow Investment Acquisitions and Disposals is fairly stable at the moment as compared to the past year. Neoleukin Therapeutics reported Net Cash Flow Investment Acquisitions and Disposals of 64.4 Million in 2019. Effect of Exchange Rate Changes on Cash is likely to rise to about 10.8 K in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (70.9 M) in 2020. While many traders today are more concerned about the preservation of capital over market returns, Neoleukin Therapeutics could be one exception. I will take a closer look at this stock and the current sentiment generated by investors. Here I will also break down some technical and fundamental indicators that the firm investors should consider in January.
Published over a month ago
View all stories for Neoleukin Therapeutics | View All Stories
What are the odds of Neoleukin Therapeutics sliding in January?
Neoleukin Therapeutics is undervalued at 13.71 per share with modest projections ahead. The company secures a Beta (Market Risk) of 0.1999, which conveys not very significant fluctuations relative to the market. Let's try to break down what Neoleukin's beta means in this case. As returns on the market increase, Neoleukin Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Neoleukin Therapeutics will be expected to be smaller as well. Even though it is essential to pay attention to Neoleukin Therapeutics price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Neoleukin Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate its performance. Neoleukin Therapeutics has an expected return of -0.0495%. Please be advised to verify Neoleukin Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Neoleukin Therapeutics stock performance from the past will be repeated at some point in the near future.

How important is Neoleukin Therapeutics's Liquidity

Neoleukin Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Neoleukin Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neoleukin Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Neoleukin Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Neoleukin Therapeutics, but it might be worth checking our own buy vs. sell analysis

Purchase by Baker Bros Advisors Lp of 518555 shares of Neoleukin Therapeutics

Legal trades by Neoleukin Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neoleukin insider trading alert for perchase of pre-funded warrants by Baker Bros Advisors Lp, the corporate stakeholder, on 23rd of December 2020. This event was filed by Neoleukin Therapeutics In with SEC on 2020-12-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Neoleukin Therapeutics Investor Appetite?

Neoleukin Therapeutics holds a total of 41.93 Million outstanding shares. Over half of Neoleukin Therapeutics outstanding shares are owned by institutional investors. These institutional investors are typically referred to corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Neoleukin Therapeutics. Please watch out for any change in the institutional holdings of Neoleukin Therapeutics as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
 2010 2019 2020 (projected)
Revenues USD25 M22.5 M22.37 M
Revenues25 M22.5 M22.37 M

Ownership Breakdown

Retail Investors
13.51%
Insiders
20.29%
Institutions
66.2%
Retail Investors13.51
Insiders20.29
Institutions66.2

Over 3 percent rise for Neoleukin Therapeutics. What does it mean for investors?

The skewness is down to -0.22 as of today. Neoleukin Therapeutics exhibits very low volatility with skewness of -0.22 and kurtosis of -0.58. However, we advise investors to further study Neoleukin Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Final Perspective on Neoleukin Therapeutics

While some other companies under the drug manufacturers?specialty & generic industry are still a bit expensive, Neoleukin Therapeutics may offer a potential longer-term growth to investors. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Neoleukin as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neoleukin Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Neoleukin Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com